摘要To the Editor:Immune checkpoint inhibitors(ICIs)interact with critical fac-tors involved in immunoregulation.Following the FDA approval of nivolumab as a second line therapy for unresectable hepatocellu-lar carcinoma(HCC)in 2017,numerous HCC patients have experi-enced benefits from ICIs[1].In 2020,the FDA approved the combi-nation of atezolizumab and bevacizumab as first line treatment for unresectable HCCs that have not undergone prior systemic treat-ments[2].ICIs are driving a transformative change in the field of cancer therapy.Several cases have been reported of using ICIs as downstaging or bridging therapy for unresectable HCC in solid or-gan transplant recipients[3].Some of these cases describe severe and sometimes fatal allograft rejection in the recipients[4-6].Here,we present a patient who was treated with a programmed cell death ligand 1(PD-L1)inhibitor,exhibited T-cell-mediated cholan-gitis and periportal inflammation,and ultimately recovered after a series of treatments.